全文获取类型
收费全文 | 14955篇 |
免费 | 1412篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 124篇 |
儿科学 | 623篇 |
妇产科学 | 296篇 |
基础医学 | 1862篇 |
口腔科学 | 353篇 |
临床医学 | 1645篇 |
内科学 | 2873篇 |
皮肤病学 | 191篇 |
神经病学 | 1360篇 |
特种医学 | 714篇 |
外科学 | 2171篇 |
综合类 | 376篇 |
一般理论 | 18篇 |
预防医学 | 1428篇 |
眼科学 | 401篇 |
药学 | 1090篇 |
中国医学 | 12篇 |
肿瘤学 | 889篇 |
出版年
2022年 | 124篇 |
2021年 | 244篇 |
2020年 | 158篇 |
2019年 | 252篇 |
2018年 | 340篇 |
2017年 | 267篇 |
2016年 | 281篇 |
2015年 | 344篇 |
2014年 | 442篇 |
2013年 | 619篇 |
2012年 | 837篇 |
2011年 | 813篇 |
2010年 | 505篇 |
2009年 | 450篇 |
2008年 | 718篇 |
2007年 | 751篇 |
2006年 | 742篇 |
2005年 | 681篇 |
2004年 | 714篇 |
2003年 | 577篇 |
2002年 | 606篇 |
2001年 | 372篇 |
2000年 | 350篇 |
1999年 | 336篇 |
1998年 | 261篇 |
1997年 | 220篇 |
1996年 | 233篇 |
1995年 | 158篇 |
1994年 | 192篇 |
1993年 | 166篇 |
1992年 | 295篇 |
1991年 | 262篇 |
1990年 | 216篇 |
1989年 | 224篇 |
1988年 | 213篇 |
1987年 | 209篇 |
1986年 | 197篇 |
1985年 | 178篇 |
1984年 | 131篇 |
1983年 | 106篇 |
1982年 | 100篇 |
1981年 | 94篇 |
1980年 | 108篇 |
1979年 | 90篇 |
1978年 | 87篇 |
1977年 | 85篇 |
1976年 | 99篇 |
1974年 | 75篇 |
1973年 | 95篇 |
1972年 | 86篇 |
排序方式: 共有10000条查询结果,搜索用时 640 毫秒
11.
12.
13.
Birger Ragnarson Göran Örnung Ole P Ottersen Gunnar Grant Brun Ulfhake 《Journal of neuroscience methods》1998,80(2):42-136
Choleragenoid (cholera toxin B-fragment; CTB) is an anterograde, retrograde and transganglionic neuronal tracer. We describe a method for detecting CTB-labeled neuronal cell bodies, neurites and boutons at the ultrastructural level, using postembedding immunogold techniques on freeze-substituted Lowicryl HM20™ embedded nervous tissue. Primary afferents and motoneurons were labeled by injection of CTB in the dorsal ramus of the C2 spinal nerve of the rat. Following fixation with paraformaldehyde (4%) and glutaraldehyde (0.25%), tissue sections from the spinal cord C2 segment were freeze-substituted and embedded in Lowicryl HM20™ and subsequently processed with postembedding immunocytochemistry for CTB and glutamate. Immunogold particles indicating CTB immunoreactivity were found over primary afferents and motoneurons. In primary afferents in the central cervical nucleus (CCN) and motor nuclei, immunogold labeling was seen in boutons over vesicle-containing axoplasm and to a lesser extent over axoplasm devoid of vesicles, but not over mitochondria or axolemma. In motoneurons, immunogold particles were seen over the Golgi apparatus in the soma and over lysosomes in both soma and dendrites. Quantification of glutamate-like immunoreactivity in 20 CTB-labeled and 20 CTB-negative boutons in the neuropil was found similar, indicating that CTB does not interfere with the immunocytochemical detection of neuronal epitopes such as the transmitter substance glutamate. 相似文献
14.
The extracellular electrophysiological properties of neurons in the laterodorsal tegmental nucleus (LDT), a major source of cholinergic afferents to the thalamus, were studied in chloral hydrate-anesthetized rats. A combination of antidromic activation from the thalamus and histological verification of recording sites was used to correlate the identity of extracellular recordings in the rat LDT with cholinergic neurons in that region. All neurons antidromically activated by stimulation of the anteroventral thalamus were histologically verified to be within clusters of cholinergic (NADPH-d-positive) cells in the LDT or in the adjacent nucleus locus coeruleus (LC). The thalamically projecting LDT neurons had a homogeneous neurophysiological profile consisting of long duration action potentials (mean = 2.5 ms), slow conduction velocities (mean = 0.78 m/s), and lengthy chronaxie values (mean = 0.725 ms). The appearance and axonal characteristics of these neurons resembled those of noradrenergic LC neurons, but the two populations exhibited substantially different spontaneous activity patterns and sensory responsiveness. These characteristics may be useful in the preliminary identification of putative cholinergic neurons in vivo, and thereby provide a foundation for exploring the neuropharmacology, afferent modulation, sensory responsiveness and behavioral correlates of the brainstem cholinergic system. 相似文献
15.
16.
17.
18.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献
19.
20.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献